Teva Is at Center of Drug Price-Fixing Case Filed by States
- States file new antitrust complaint naming company executives
- Pricing scheme allegedly cost consumers billions of dollars
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. helped mastermind a sweeping conspiracy among generic drugmakers to raise the price of medicines, according to a new antitrust lawsuit filed by states that stems from a five-year investigation of the companies. Teva’s stock plunged the most in three months.
More than a dozen current and former executives at top generic-drug makers, including Mylan NV and a unit of Pfizer Inc., were sued on Friday by more than 40 states led by Connecticut Attorney General William Tong.